RYE | Jotup

Benchmark at Rye Executive Director Receives Annual "President's Award"

Retrieved on:

Monday, April 15, 2024

Bed, Caregiver, Barash, Rye, Amnesia, RYE, Dementia

RYE, N.H., April 15, 2024 /PRNewswire-PRWeb/ -- Benchmark, the largest senior living provider in New England, today announced that Nick Barash of Andover, Mass., executive director of Benchmark at Rye, a Mind & Memory Care community, has received the Benchmark 2023 President's Award, which is the Waltham-based company's highest honor for associates in a senior leadership role.

Key Points:

RYE, N.H., April 15, 2024 /PRNewswire-PRWeb/ -- Benchmark , the largest senior living provider in New England, today announced that Nick Barash of Andover, Mass., executive director of Benchmark at Rye , a Mind & Memory Care community, has received the Benchmark 2023 President's Award, which is the Waltham-based company's highest honor for associates in a senior leadership role.
-Tom Grape, founder, chairman and CEO, Benchmark Senior Living
At the company's 21st Annual Awards Gala held on March 7, 2024, Barash was selected for exhibiting outstanding operational leadership at his previous community, Benchmark Senior Living at Haverhill Crossings and at his present community, Benchmark at Rye, a memory care assisted living community.
Barash was hailed for frequently going above and beyond for residents, their families and associates, which has resulted in increased satisfaction across the community.
"The compassion and care our associates exhibit daily is truly inspiring," said Tom Grape, founder, chairman and CEO of Benchmark.

Anteriad Named A Strong Performer Among B2B Marketing and Sales Data Providers in Major Research Report

Retrieved on:

Wednesday, March 13, 2024

Innovation, Sale, Acquisition, RYE, Marketing, Data collection, Service, ABM

RYE BROOK, N.Y., March 13, 2024 (GLOBE NEWSWIRE) -- Anteriad, the global B2B marketing solutions provider, today announced that the company has been named a Strong Performer in The Forrester Wave™: Marketing and Sales Data Providers for B2B, Q1 2024.

Key Points:

RYE BROOK, N.Y., March 13, 2024 (GLOBE NEWSWIRE) -- Anteriad, the global B2B marketing solutions provider, today announced that the company has been named a Strong Performer in The Forrester Wave™: Marketing and Sales Data Providers for B2B, Q1 2024.
Anteriad placed in the top five in the strategy category, highlighting for them, the strength of the company’s vision and plan for delivering value to customers in the future.
Our data not only performs exceptionally well, but it also scales for enterprise customers with needs from awareness to closed sale,” said Rob Sanchez, CEO at Anteriad.
Access The Forrester Wave™: Marketing and Sales Data Providers for B2B, Q1 2024 here .

KLAFTER LESSER LLP ANNOUNCES THAT THE DISTRICT OF COLUMBIA LAW BY WHICH IT HAS REQUIRED NON-RESIDENT (BUT NOT RESIDENT) SEMIPUBLIC INSTITUTIONS TO PAY SALES AND HOTEL TAXES HAS BEEN HELD TO VIOLATE THE U.S. CONSTITUTION

Retrieved on:

Thursday, April 4, 2024

Organization, Tax, Constitution, Clause, Commerce Clause, CVT, American Anthropological Association, American Philosophical Association, RYE, Commerce, Superior court, Court

That Clause prohibits a state, including the District, from discriminating against out-of-state entities when they participate in its economy.

Key Points:

That Clause prohibits a state, including the District, from discriminating against out-of-state entities when they participate in its economy.
Thus, the District, in favoring its own resident organizations, was found to have discriminated un-Constitutionally against such entities from other states.
Not a single other state imposes a residency requirement on semipublic institutions in order to obtain a tax exemption when engaging in commerce in it.
Despite this ruling, the District continues to unlawfully refuse to provide non-resident semipublic institutions with a tax exemption when engaging in commerce in the District.

Cyclists Take On America's Most Beautiful Bike Ride In Support Of Blood Cancer Patients

Retrieved on:

Wednesday, April 3, 2024

Diagnosis, Team In Training, Acute lymphoblastic leukemia, Bone marrow, University of Nevada, Reno, Leukemia & Lymphoma Society, Leukemia, Patient, SVP, Research, Perspiration, Cancer, University, RYE, Quality of life, LLS, Reader

RYE BROOK, N.Y., April 3, 2024 /PRNewswire/ -- Cyclists from across the country will help change the lives of blood cancer patients by gathering in Lake Tahoe on June 2, 2024 to participate in America's Most Beautiful Bike Ride. While working up a sweat and enjoying breathtaking views, riders' efforts will drive forward the work of The Leukemia & Lymphoma Society (LLS) to fund groundbreaking research, provide free patient support and assistance, and advocate on behalf of blood cancer patients and their families.

Key Points:

In its efforts to reach and help all those impacted by a blood cancer diagnosis, LLS actively partners in communities across the country.
This year, LLS welcomes WVU Cancer Institute as America's Most Beautiful Bike's premier sponsor and new venue partner Tahoe Blue Event Center.
This year, America's Most Beautiful Bike Ride has chosen leukemia survivor Greg Carlson as the event's Honored Hero.
WHY: To support LLS and make an impact in the lives of all those affected by a blood cancer diagnosis.

Bringing Light to The Darkness of Cancer: BeiGene Named National Partner of Survivorship and Hope for The Leukemia & Lymphoma Society's Light The Night

Retrieved on:

Tuesday, March 12, 2024

"BeiGene is proud to expand our partnership with the Leukemia and Lymphoma Society this year as the National Presenting Sponsor of Survivorship and Hope for Light The Night," Josh Neiman, Chief Commercial Officer at BeiGene, said.

Key Points:

"BeiGene is proud to expand our partnership with the Leukemia and Lymphoma Society this year as the National Presenting Sponsor of Survivorship and Hope for Light The Night," Josh Neiman, Chief Commercial Officer at BeiGene, said.
"LLS's Light The Night inspires communities, bringing more people out of the darkness of cancer, shining a light on survivors everywhere.
BeiGene has been supporting LLS's Light The Night for the past five years, and before becoming the National Presenting Sponsor of Survivorship and Hope, was a Light The Night National Sponsor in 2022 and 2023.
To join Light The Night and shine a light on survivorship and hope, visit www.lightthenight.org .

Business & Community Leaders Join The Leukemia & Lymphoma Society's 2024 Visionaries Of The Year Annual Philanthropic Competition To Champion A World Without Blood Cancer

Retrieved on:

Tuesday, March 5, 2024

Leukemia, Bone marrow, Senior, LLS, Education, Quality of life, Volunteering, Leukemia & Lymphoma Society, Patient, Policy, Research, RYE, Visionaries, Birth control

Now underway for the 35th consecutive year, business and community leaders committed to improving the lives of those impacted by blood cancer are engaging in a little healthy competition through LLS's Visionaries of the Year campaign.

Key Points:

Now underway for the 35th consecutive year, business and community leaders committed to improving the lives of those impacted by blood cancer are engaging in a little healthy competition through LLS's Visionaries of the Year campaign.
Participants of this have 10 weeks to raise funds that will directly support LLS's life-changing work.
LLS recognizes these inspiring individuals as "Visionaries," who are dedicated volunteers fundraising and creating awareness about blood cancer in their communities.
"Together, we will find cures and improve the quality of life for all those affected and ultimately create a world without blood cancer."

Curemark Announces the Addition of Christopher Varelas to the Board of Directors

Retrieved on:

Thursday, February 1, 2024

Salomon, National Investment Bank, Head, Aspen Institute, The New York Times, Partner, RYE, Aspen

RYE BROOK, N.Y., Feb. 1, 2024 /PRNewswire/ -- Curemark, LLC announced the appointment of Chris Varelas to its Board of Directors.

Key Points:

RYE BROOK, N.Y., Feb. 1, 2024 /PRNewswire/ -- Curemark, LLC announced the appointment of Chris Varelas to its Board of Directors.
Mr. Varelas is a Co-founding Partner of Riverwood Capital, an investment firm focused on high-growth technology and technology-related companies.
Dr. Joan Fallon, Curemark's CEO and Founder, said, "We are extremely excited to welcome Chris to our board.
As Curemark's growth continues to accelerate, his decades of experience in banking, finance and M&A will be invaluable as we navigate the path to commercialization."

Bronxville's 15 Parkview Now Available for Rent

Retrieved on:

Tuesday, December 12, 2023

St Lawrence's Hospital, Bodmin, Hospital, Architecture, Self storage, Interior design, RYE

RYE, N.Y., Dec. 12, 2023 /PRNewswire/ -- Elk Homes, a leading developer of luxury residential rental properties in lower Westchester and Greenwich, Connecticut, announces that leasing has commenced at its newest venture, 15 Parkview Avenue in Bronxville. This building marks the first upscale rental development in Garrett Park and Bronxville in decades, ushering in a new era of architecture and contemporary living for the community.

Key Points:

RYE, N.Y., Dec. 12, 2023 /PRNewswire/ -- Elk Homes, a leading developer of luxury residential rental properties in lower Westchester and Greenwich, Connecticut, announces that leasing has commenced at its newest venture, 15 Parkview Avenue in Bronxville.
Comprising an 80,000-square-foot newly constructed residential building, 15 Parkview offers 60 spacious and meticulously designed apartments.
15 Parkview Avenue is a short walk to the Bronxville train station, the local shopping area, and New York-Presbyterian Westchester (formerly Lawrence) Hospital.
"15 Parkview is the pinnacle of Westchester living," said Gary Hirsch, CEO of Elk Homes.

The Leukemia & Lymphoma Society Honors Five Outstanding Blood Cancer Scientists with 2023 Awards

Retrieved on:

Monday, December 11, 2023

Humanitarian Scientists Honored for Service to LLS, Blood Cancer Community

Key Points:

Humanitarian Scientists Honored for Service to LLS, Blood Cancer Community
The Excellence in Scientific Service award recognizes outstanding scientists who have made exceptional contributions to blood cancer research and have also generously given their time and expertise to help LLS find and fund the brightest scientists and most innovative biotech companies working to cure all forms of blood cancer.
"LLS is the premier organization supporting blood cancer research, and I have been privileged for the opportunity to support their efforts.
2023 LLS-CDP Clinical Scholar Achievement Awardee, Matthew Davids, M.D., is Associate Professor of Medicine and Leader of the Lymphoma Program for Dana-Farber/Harvard Cancer Center.
LLS hosts the Research Awards & Networking Event annually timed to the American Society of Hematology (ASH) annual meeting.

The Leukemia & Lymphoma Society (LLS) Data and Presence at ASH Showcase Latest Blood Cancer Treatment Breakthroughs

Retrieved on:

Tuesday, December 5, 2023

RYE BROOK, N.Y., Dec. 5, 2023 /PRNewswire/ -- At the 65th Annual American Society of Hematology (ASH) Annual Meeting (December 9-12 in San Diego), The Leukemia & Lymphoma Society (LLS) will present new research findings, and proudly support more than 200 LLS-funded researchers, as well as 15 current and former LLS Therapy Acceleration Program® (TAP) partners, who will share their study results.

Key Points:

The next big advances are in the works," said Lee Greenberger, Ph.D., LLS Chief Scientific Officer.
LLS funding has helped advance more than 70% of blood cancer treatment options approved by the U.S. Food and Drug Administration in the last six years.
LLS research selected for presentation at ASH includes:
New data from two master clinical trials convened and led by LLS: the Pediatric Acute Leukemia Master Clinical Trial ( PedAL ) and the Beat AML® Master Clinical Trial .
The Beat AML Master Clinical Trial, the first collaborative precision medicine clinical trial in blood cancer, uses advanced technology to provide genomic analysis to match patients to precision treatment within seven days.